- Home
- LQDA
LQDA
Liquidia Corporation
as 03-12-2025 4:00pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 1.3B | IPO Year: | 2018 |
| Target Price: | $26.67 | AVG Volume (30 days): | 859.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.26 - $16.99 | Next Earning Date: | 05-12-2025 |
| Revenue: | $15,610,000 | Revenue Growth: | -14.78% |
| Revenue Growth (this year): | -7.38% | Revenue Growth (next year): | 208.28% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Moomaw Scott | LQDA | Chief Commercial Officer | Feb 28 '25 | Sell | $15.45 | 592 | $9,146.40 | 218,150 | |
| Kaseta Michael | LQDA | CFO and COO | Feb 28 '25 | Sell | $15.45 | 874 | $13,503.30 | 404,598 | |
| Adair Jason | LQDA | Chief Business Officer | Feb 28 '25 | Sell | $15.45 | 451 | $6,967.95 | 182,254 | |
| Schundler Russell | LQDA | General Counsel | Feb 28 '25 | Sell | $15.45 | 930 | $14,368.50 | 576,265 | |
| Adair Jason | LQDA | Chief Business Officer | Jan 27 '25 | Sell | $14.20 | 445 | $6,319.00 | 182,254 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Jan 21 '25 | Sell | $13.00 | 2,445 | $31,785.00 | 267,943 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Jan 11 '25 | Sell | $11.78 | 8,362 | $98,504.36 | 218,150 | |
| JEFFS ROGER | LQDA | Chief Executive Officer | Jan 11 '25 | Sell | $11.78 | 22,343 | $263,200.54 | 1,019,177 | |
| Kaseta Michael | LQDA | CFO and COO | Jan 11 '25 | Sell | $11.78 | 23,370 | $275,298.60 | 404,598 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Jan 11 '25 | Sell | $11.78 | 6,249 | $73,613.22 | 267,943 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
GlobeNewswire
17 days ago
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
Simply Wall St.
20 days ago
US Growth Stocks With High Insider Ownership Seeing Up To 48% Revenue Growth
Zacks
2 months ago
Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last?
Simply Wall St.
2 months ago
3 US Growth Stocks With Strong Insider Ownership
MT Newswires
2 months ago
Liquidia Insider Sold Shares Worth $275,299, According to a Recent SEC Filing
GlobeNewswire
2 months ago
Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
2 months ago
Jim Cramer’s Hidden Gem: Why Liquidia Corporation (LQDA) Is the Undervalued Stock You Need to Know
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.